Kornimate/medical-research-clean huggingface dataset:
fatty acid taste thresholds: caproic, lauric, oleic, linoleic, linolenic

Conditions: Taste Sensitivity; Fatty Acid Type

Summary: differences in human oral sensitivity for caproic, lauric, oleic, linoleic, and linolenic acids will be explored. prior work indicates that there may be a learning effect in measuring detection thresholds for free fatty acids. this study is designed to determine the number of visits necessary to attenuate this learning effect and also to test whether this effect continues across different types of fatty acids or is specific to each fatty acid. this will aid in understanding how many visits are required to obtain reliable data and if less expensive fatty acids can be used to attenuate learning before testing thresholds for more expensive fatty acids.


Eligibility criteria:
inclusion criteria: * 18-60 years of age * in good health * available for 3 months exclusion criteria: * participation in a different fat taste study in previous 6 months

Keywords: taste non-esterified fatty acids threshold sensitivity human
localized effects of pbm and exogenous no on crest patients calcinosis cutis & raynaud phenomenon

Conditions: CREST Syndrome; Calcinosis Cutis; Raynaud Phenomenon

Summary: background crest is an acronym for the cardinal clinical features of the syndrome (calcinosis, raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia) and part of the heterogeneous group of sclerodermas. calcinosis is the pathologic calcification of soft tissues. when symptomatic, they can be tender and painful, ulcerate, and drain a white chalky substance. with time, heterotopic bone formation may occur. inflammatory reactions also intermittently occur at the site of calcinosis. it has been suggested that tgf-beta3 plays a major role in the pathogenesis of calcinosis. a variety of medical therapies have been used to try to alleviate patient symptoms. these include pharmacological approaches (e..g., warfarin), surgical curettage or excision, as well as carbon dioxide laser treatments. no consistently reliable pharmacological treatment seems to be available to prevent or eliminate calcinosis. curettage and excision and carbon dioxide laser of localized painful large deposits can relieve symptoms but recurrence is common. in addition, aggressive curettage or excision can damage deeper neurovascular structures. while calcinosis is associated with significant morbidity its treatment remains a challenge. photobiomodulation (pbm) has been shown to promote wound healing, suppress inflammatory reactions and regulate collagen synthesis in a number of in vitro and in vivo studies. human skin contains photolabile nitric oxide (no) derivatives which decompose after uva irradiation and release vasoactive no. however, aside from blue light, barely nothing has been reported about the effects of red and nir wavelengths. method a custom-built air tight sleeve which envelopes the forearm of a subject will be used to measure the no emanating from the skin under photobiomodulation conditions (red \& nir) and quantified by chemiluminescence detection. simultaneously, crest patient's hands exhibiting calcinosis and/or raynaud phenomenon will be exposed to exogenous gaseous nitric oxide (inomax) to determine the vascular impact of this approach. this case series will assess light emitting diode (led) based pbm therapy as a treatment alternative for cutaneous calcinosis and the effects of gaseous no on calcinosis and/or raynaud phenomenon in crest patients.


Eligibility criteria:
inclusion criteria: * male or female * 18-60 years of age * crest syndrome with calcinosis cutis. * crest syndrome without calcinosis cutis. exclusion criteria: * diabetes mellitus * acute inflammation * arrhythmia * acute malignancy * renal failure * active cvd * photodermatosis and/or photosensitivity including skin cancer-prone disease/syndrome (xp and bloom syndrome) * porphyria and/or hypersensitivity to porphyrins * congenital or acquired immunodeficiency.

Keywords: nitric oxide photobiomodulation lllt photomedicine
optimised lung cancer screening to prevent cardiovascular and pulmonary diseases coupled with primary prevention

Conditions: Lung Cancer; Cardiovascular Disease (CVD); Chronic Obstructive Pulmonary Disease (COPD)

Summary: this project aims to implement a health prevention program for smokers or former smokers including early detection of lung cancer, cardiovascular disease (cvd) and chronic obstructive pulmonary disease (copd). the clinical activity is completed by a pre-clinical evaluation of molecular bio-markers of early diagnosis of these diseases, with the aim of strengthening the sensitivity and specificity of the screening program. the project also includes a cost-effectiveness assessment to validate the feasibility of the program. since lung cancer, cvd and copd are among the deadliest smoking-related pathologies, the program includes actions aimed at raising awareness among primary care physicians, increasing the smoking cessation rate of participating subjects to improve quality of life.


Eligibility criteria:
inclusion criteria: * age ≥ 55 years old and exposure to smoking more than 30 packs-year; which corresponds to 6-year risk of lung cancer, calculated according to the plco score (≥ 2%). * smoker or former smoker former smokers must have ceased smoking within the 15 years prior to enrollment in the study. * absence of symptoms of lung cancer such as worsening of cough, hoarseness, hemoptysis and weight loss. exclusion criteria: * previous diagnosis of lung cancer. * positive extrapulmonary cancer history in the last 5 years (excluding in situ tumors or skin epidermoid tumor). * performing a chest ct scan in the last 18 months. * severe lung or extrapulmonary diseases that may preclude or invalidate appropriate therapy in case of diagnosis of malignant pulmonary neoplasia.

Keywords: cancer risk prevention cancer risk reduction cardiovascluar disease prevention micrornas copd prevention lung cancer circulating biomarkers lung cancer screening minimally invasive surgery low dose computed tomography (ldct)
anti-neoplastic treatment, based on pro data reported through a mhealth app solution in multiple myeloma

Conditions: Multiple Myeloma

Summary: pirmary endpoint: to examine the feasibility of using an mhealth app for reporting of side effects instead of a telephone call from the hospital staff together with examining the perspectives of patients with multiple myeloma and healthcare professionals of this new method for reporting side effects, and to assess organizational aspects. usual procedure to assess side effect prior to cancer treatment with bortezomib is a telephone call the day before. with this innovative method investigator aimed to give the patient more independence in their daily life and in that way improve their quality of life.

it is a prospective, clinical, parallel mixed-method design with a quantitative core and a qulitative supplementary component. there will be used a mhealth app called "my hospital". quantitative data will be acquired from time registrations performed by patients and nurses and will be descriptively analyzed applying a micro-costing approach, using cost data per individual. qualitative data will be obtained from individual, semi-structured interviews with patients and one focus group interview with healthcare professionals and will be analyzed applying a hermeneutic approach. eligible for inclusion were patients with mm scheduled for bortezomib. moreover, patients should have access to a smartphone, be able to self-report side effects of bortezomib using a smartphone app, and be willing to participate in a semi-structured interview.

Eligibility criteria:
inclusion criteria: * patients with mm scheduled for bortezomib * patients should have access to a smartphone * patients should be able to self-report side effects of bortezomib using a smartphone app, and be willing to participate in a semi-structured interview. exclusion criteria: * patients had to talk and read danish
effects of combined cognitive training with aerobic exercise in stroke patients with mci

Conditions: Stroke

Summary: cognitive impairments have severe impact on functional recovery and quality of life after stroke. current evidence indicated that combining exercise and cognitive training may provide additional benefits on cognition in stroke. this study aims to investigate the effects and mechanisms of two combined methods of computer-based cognitive training with physical exercise in stroke patients with cognitive impairments.

cognitive impairment is not uncommon after stroke. stroke patients with cognitive decline may experience difficulties in learning motor tasks, functional disability, and poor quality of life. interventions for cognitive impairment remain under development and pharmaceutical intervention is not yet optimal at present. targeted cognitive treatments or aerobic exercise training provided potential benefits to enhance cognitive function for stroke patients with cognitive decline. recent studies demonstrate that combining exercise and cognitive training may provide additional benefits on cognition than single type of training. however, physical exercise training and cognitive-based intervention can be combined either sequentially or simultaneously. it remains unclear whether the two combination methods induce similar or differential effects in brain plasticity, physiological modulation, and behavioral outcomes for individuals with stroke. it is important to examine the potential effects, comparative effects and the neural mechanism of two combined interventions that can possibly maximize benefits for stroke survivors with cognitive impairments. the purposes of the present study are to: (1) examine and compare the effects of two combined interventions on brain plasticity, physiological biomarkers and behavioral outcomes, including cognitive, physical, and daily functions, and quality of life, from pre- to post-training; (2) understand the neural mechanisms of cognitive recovery following two combined interventions using the electroencephalography (eeg); (3) examine the long-term benefits following the two combined interventions; (4) to identify the correlations between brain activity, biomarkers and behavioral measures.

Eligibility criteria:
inclusion criteria: 1. ischemic or hemorrhagic stroke occurring at least 6 months prior to enrollment 2. age range from 20 to 90 years 3. mmse score \< 28, or moca score \< 25 4. self- or informant-reported memory or cognitive complaints or clinical dementia rating (cdr) scale ≤ 0.5 5. able to follow the study instruction 6. adequate cardiopulmonary function to perform aerobic exercise 7. able to walk with or without assistive devices exclusion criteria: 1. unstable medical history (e.g., recent myocardial infarction) that might limit participation 2. concomitant with other neurological disorders (e.g., parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis) 3. current participation in another interventional trial

Keywords: cognitive rehabilitation aerobic exercise computerized cognitive training
vibration anesthesia for propofol- rocuronium injection pain

Conditions: Vibration; Pain Due to Certain Specified Procedures

Summary: despite numerous strategies for preventing or alleviating pain associated with propofol and rocuronium injections, it remains common and distressing for patients. vibration is an effective method of reducing pain during facial cosmetic injections and some venipuncture procedures. but it has not been previously studied in the context of propofol or rocuronium injection pain. this randomized study aims to evaluate the effect of vibration anesthesia on the incidence and severity of propofol and rocuronium injection pain.

due to their rapid onset and short duration of action, ease of titration, recovery, and favorable profile for side effects, propofol and rocuronium are agents frequently used together in anesthesia practice and for rapid-sequence intubation. however, both cause severe discomfort due to pain in the injection arm. some patients recall the induction of anesthesia as the most painful part of the perioperative period. vibration anesthesia has repeatedly been shown to alleviate pain sensation effectively and safely. vibration anesthesia device is designed to reduce the pain from minor procedures, such as injection of medications, suture or staple removal, phlebotomy and even venipuncture pain in pediatric patients. the advantages of this device include its low cost, lack of adverse effects, and ease of use. it has been shown to reduce pain with a mechanism based on the gate control theory, which states that vibrations stimulate the dorsal horn neurons, the sites at which pain signals are modulated and thus block full transmission of the pain.the investigators therefore proposed this randomized controlled study to compare the effectiveness of a vibration device for propofol and rocuronium injection pain during general anesthesia induction.

Eligibility criteria:
inclusion criteria: * asa i-ii patients * patients who are planned to undergo gynecology operations exclusion criteria: * participants who were pregnant, * patients who had a recent history of a severe allergic or hypersensitivity reaction to propofol or rocuronium

Keywords: vibration analgesia propofol injection pain rocuronium injection pain
effects of a digital health application (lipodia) on ldl-cholesterol levels

Conditions: Hypercholesterolemia; Dyslipidemias

Summary: the goal of this clinical trial is to find out if lipodia, a digital health intervention, can help lower cholesterol levels and improve other health measures in adults with high cholesterol. the main questions it aims to answer are: * does lipodia, together with regular treatment, lower ldl cholesterol (bad cholesterol) better than regular treatment alone? * does lipodia help improve other health outcomes, like how confident participants feel in managing their health? researchers will compare two groups: * intervention group: participants use the lipodia intervention and continue their usual treatment. * control group: participants continue with their usual treatment only. participants will: * fill out questionnaires online and visit a certified lab at the start of the study, after 3 months, and after 6 months * have blood tests at each lab visit to check their cholesterol and other blood fat levels * continue with their usual treatment (both groups) and use lipodia, a digital health app, for six months (intervention group only)


Eligibility criteria:
inclusion criteria * age ≥ 18 * diagnosis of hypercholesterolemia (icd-10 e78.0, e78.2, e78.4, e78.5, e78.8, e78.9) confirmed by a laboratory test and physician diagnosis * ldl-c levels above risk-adapted target * tg levels \< 400 mg/dl * stability of potential drug treatment during the last 4 weeks * stability of potential hormonal treatment during the last 6 months * patient was made aware of lifestyle measures by gp or specialist * consent to participation * sufficient knowledge of the german language exclusion criteria * homozygous familial hypercholesterolemia (fh), given that it is a genetic condition which is relatively unresponsive to lifestyle changes * hyperlipidemia type iii, given that it is a genetic condition which is relatively unresponsive to lifestyle changes * patients receiving plasmapheresis * lp(a) \> 50 mg/dl * current pregnancy or planned pregnancy during the study period * planned major operations * liver dysfunction * end-stage renal failure * other systemic conditions that might interfere with successful study participation * plans to change drug (including hormonal) treatment in the upcoming 6 months * use of another digital intervention for hypercholesterolemia/dyslipidemia in the past

Keywords: ldl-c digital intervention
clinical investigation to evaluate the ability of mammowave in breast lesions detection

Conditions: Breast Cancer

Summary: this is a multicentric, single arm, prospective, stratified by breast density clinical investigation using mammowave that is a device, which uses microwaves instead of ionizing radiation (x-ray)for breast lesions(bl) detection. specifically, mammowave employs a novel technique which generates images by processing very low power (\<1 mw) microwaves. the exam takes few minutes per breast and is performed with the patient lying in a comfortable facing down position. mammowave is safe to be used at any age, in any condition (pregnancy, specific illness) and for unlimited number of times.

the number of participants will be 500 (for all the sites). the study will be composed of two phases: a preliminary phase to 'optimize the imaging algorithm for each apparatus installed at each centre', where 15 healthy volunteers in each centre will be examined by mammowave. in the second phase, the remaining people will be enrolled (breast lesions pts will be about 70% of total) and examined by mammowave by the clinical investigator, and results will be compared with the effective diagnosis already obtained by standard clinical methods. bl includes malignant lesions (bc) and benign lesions, and may be palpable or non-palpable lesions. bl includes also isolated clustered microcalcifications. at the end of the study, in each centre the clinical investigators will compare mammowave output against the radiologist study output obtained using conventional exams. in addition, at the end of the study, the mammowave output will be centrally reviewed in blind by an independent radiologist in order to confirm the data and confirm centrally the comparisons performed locally. the primary goal of the clinical study is to assess mammowave's ability in bl detection and differentiation.

Eligibility criteria:
inclusion criteria: 1. signed informed consent form 2. women 3. adult ≥18 years old 4. having a radiologist study output obtained using conventional exams (such as breast specialist visit and mammography and/or ultrasound and/or magnetic resonance imaging) within the last month. 5. patients willing to comply with study protocol and recommendations. 6. patients with intact breast skin (i.e. without bleeding lesion, scar). exclusion criteria: 1. patients that are enrolled in another clinical study 2. patients who belong to any vulnerable group. 3. patients with implanted electronics. 4. patients who have undergone biopsy less than one week before mammowave scan 5. patients with breast implants 6. patients with nipple piercings (unless they are removed before mammowave exam). 7. participation in other studies in the last month before screening 8. pregnancy or breastfeeding
a clinical study to evaluate the safety, tolerability, and preliminary efficacy of b019 injection in subjects with relapsed or refractory b-cell acute lymphoblastic leukemia.

Conditions: Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Summary: the purpose of the study is to evaluate the safety and tolerability of b019 in subjects.


Eligibility criteria:
inclusion criteria: 1. the patient himself/herself , and/or his/her legal guardian, agree to participate in the trial and sign the informed consent form； 2. meet the diagnostic criteria for recurrent or refractory acute b cell lymphoblastic leukemia； 3. documentation of cd19/cd22 tumor expression 3. liver, kidney, lung and heart function meet requirements; 4. expected survival \>3 months; 5. women of childbearing age and all post-adolescent male participants are willing to use highly effective contraceptive methods within 1 year after the infusion of b019 injection. at the same time, the subject should promise not to donate eggs or sperm for assisted reproduction for 1 year after the cell infusion. - exclusion criteria: 1. active cns involvement by malignancy； 2. isolated extramedullary leukemia recurrence； 3. subjects with ≥grade 2 acute or moderate to severe chronic graft-versus-host disease (gvhd) within 4 weeks prior to screening; 4. has had treatment with any prior car-t therapy or other therapy abandoned in protocal. 4. subjects who received therapy abandoned in protocal before pbmc (peripheral blood mononuclear cells) collection or before b019 injection; 5.active other malignancy in 5 years. 6. subjects who are positive for any of hbsag, hbeag, hbeab, hbcab, hcv-rna, hiv ebv dna, cmv dna, htlv-ab. 7. other situations deemed inappropriate for participation in this study by the investigator. -
triple in asthma dose finding

Conditions: Asthma

Summary: the purpose of this study is to determine the optimal dose of chf 5259 (glycopyrrolate bromide) on top of foster which provides the optimal additive bronchodilator effect to asthmatic patients whose symptoms are uncontrolled with medium dose of inhaled corticosteroids plus long acting beta2 agonists.


Eligibility criteria:
inclusion criteria: * male or female patients aged \>=18 years * uncontrolled asthma on medium doses of ics+laba with acq \>=1.5 * pre-bronchodilator fev1 ≥40% and \<80% of their predicted normal value exclusion criteria: * pregnant or lactating women * diagnosis of copd * patients treated for asthma exacerbations in the 4 weeks prior to study entry * patients who are in therapy for gastroesophageal reflux disease * patients who have a clinically significant cardiovascular condition

Keywords: asthma, anticholinergics
survey of tourniquet use in a combat support hospital

Conditions: Vascular Injury

Summary: data will be collected on the type of tourniquet and circumstances of its use. patients with penetrating extremity injury will have clinical and pre-clinical hospital data collected.

this is a performance improvement project that is a prospective observational cohort design with subgroup analyses. this project meets the criteria of research with its intent to publish. no data is generated and only existing data are used. no interventions are made and the comparisons will be with within subgroups in the cohort. aim 1. describe the number of tourniquets which were appropriately used (wound required a tourniquet and tourniquet was placed properly) as assessed by treating physician aim 2 \&3. describe if limbs wounds with tourniquets were bleeding upon admission, resuscitation, and following tourniquet removal aim 4. describe if mortality for the cohort of patients with tourniquets is different than the mortality predicted by various injury scoring systems aim 5. compare patient outcomes between those in which a tourniquet was indicated but not used and those for whom a tourniquet was indicated and used aim 6. determine if patients that received tourniquets for an extended time period exhibit any known tourniquet complications

Eligibility criteria:
inclusion criteria: * penetrating extremity injury with tourniquet use exclusion criteria: * non penetrating extremity injury

Keywords: tourniquet extremity injury hemostatic device